Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI4276
- Development stage
- Phase 1
- Lead developer
- MedImmune
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MEDI4276 is an investigational biparatopic tetravalent antibody-drug conjugate (ADC) designed to target human epidermal growth receptor 2 (HER2). It consists of a bispecific humanized monoclonal antibody that binds two nonoverlapping epitopes in subdomains 2 and 4 of the HER2 ectodomain, site-specifically conjugated to a tubulysin-based microtubule inhibitor payload via a cleavable linker. Upon binding to HER2-expressing tumor cells, the ADC is internalized and releases its cytotoxic payload, leading to cell death. Developed for the treatment of advanced or metastatic HER2-positive breast cancer and gastric cancer, it demonstrated clinical activity but was discontinued due to intolerable toxicity at higher doses[1][5][10].
- Other names
- anti-HER2 antibody-drug conjugate MEDI4276anti-HER-2 antibody-drug conjugate MEDI4276anti-HER 2 antibody-drug conjugate MEDI4276
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on MEDI4276.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI4276.